Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Treprostinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 12/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 3/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 3/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 2/20 | 1.00 |
| ▸ | PTGFR | P43088 | 6/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Treprostinil SCHEMBL11914201 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL4349622 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL14732787 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL11953002 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL4349618 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL24243789 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL4349627 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL22282429 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL21530472 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL16342147 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126589-A1 | Pulmonary Delivery of Messenger RNA | ETHRIS GMBH (DE) | 2015-05-07 | — | — | US | claimed |
| JP-6087749-A | — | — | None | — | — | JP | disclosed |
| EP-4620525-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250195531-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-12263174-B2 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | Respira Therapeutics, Inc. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240109834-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | INSMED INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-20230250051-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | INSMED INCORPORATED (US) | 2023-08-10 | — | — | US | disclosed |
| US-11491160-B2 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | Respira Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11491161-B2 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | Respira Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220347183-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2022-11-03 | — | — | US | disclosed |
| US-20150148414-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | BIOPHARMA CREDIT PLC (GB) | 2015-05-28 | — | — | US | disclosed |
| US-20150126761-A1 | IMPROVED PROCESS FOR THE PREPARATION OF TREPROSTINIL AND DERIVATIVES THEREOF | SCIPHARM SARL (LU) | 2015-05-07 | — | — | US | disclosed |
| US-20150126589-A1 | Pulmonary Delivery of Messenger RNA | ETHRIS GMBH (DE) | 2015-05-07 | — | — | US | disclosed |
| WO-2015061720-A2 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | INSMED INCORPORATED (US) | 2015-04-30 | — | — | WO | disclosed |
| WO-2014203278-A3 | NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-02-26 | — | — | WO | disclosed |
| WO-2014203278-A3 | NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-02-26 | — | — | WO | disclosed |
| WO-2014203278-A2 | NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID | MSN LABORATORIES PRIVATE LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014203278-A2 | NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID | MSN LABORATORIES PRIVATE LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| JP-H0687749-A | PROSTAGLANDIN ANALOGUE FOR USE IN MEDICINE | WELLCOME FOUND LTD:THE | 1994-03-29 | — | — | JP | disclosed |
| US-5234953-A | 9-Deoxy-2'9-methano-3-oxa-4,5,6-trinor-3,7'-(1'3-inter-phenylene) -13,14-dihydroprostaglandin F1; vasodilation | BURROUGHS WELLCOME CO. (US) | 1993-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250051-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | PTGIS, THOP1, PTGIR | PTGIR 3/4885PTGER2 22/4885PTGER1 4/4885 |
| US-20150148414-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGIR, PTGER1 | PTGIR 2/4885PTGER2 6/4885PTGER1 3/4885 |
| US-20240109834-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGIR, PTGER1 | PTGIR 2/4885PTGER2 6/4885PTGER1 3/4885 |
| US-20150126761-A1 | IMPROVED PROCESS FOR THE PREPARATION OF TREPROSTINIL AND DERIVATIVES THEREOF | TREH, TPP1, TPP2 | PTGIR 280/4885PTGER2 1044/4885PTGER1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.